Capital Advisors Inc. OK increased its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 3.5% in the 1st quarter, according to its most recent filing with the SEC. The fund owned 346,804 shares of the company's stock after purchasing an additional 11,793 shares during the period. AbbVie accounts for about 1.4% of Capital Advisors Inc. OK's holdings, making the stock its 18th biggest holding. Capital Advisors Inc. OK's holdings in AbbVie were worth $72,662,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also made changes to their positions in the company. EnRich Financial Partners LLC increased its position in AbbVie by 196.4% in the 4th quarter. EnRich Financial Partners LLC now owns 166 shares of the company's stock valued at $29,000 after acquiring an additional 110 shares during the period. Prudent Man Investment Management Inc. acquired a new position in AbbVie in the 4th quarter valued at about $32,000. Siemens Fonds Invest GmbH increased its position in AbbVie by 197.6% in the 4th quarter. Siemens Fonds Invest GmbH now owns 179,440 shares of the company's stock valued at $32,000 after acquiring an additional 119,141 shares during the period. Pinney & Scofield Inc. acquired a new position in AbbVie in the 4th quarter valued at about $36,000. Finally, Redwood Park Advisors LLC acquired a new position in AbbVie in the 4th quarter valued at about $40,000. 70.23% of the stock is owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
Several equities analysts have issued reports on the company. Evercore ISI boosted their target price on AbbVie from $204.00 to $205.00 and gave the stock an "outperform" rating in a research report on Monday, April 28th. Morgan Stanley boosted their target price on AbbVie from $241.00 to $250.00 and gave the stock an "overweight" rating in a research report on Monday, April 28th. Bank of America boosted their target price on AbbVie to $204.00 and gave the stock a "hold" rating in a research report on Monday, June 9th. BNP Paribas upgraded AbbVie to a "hold" rating in a research report on Thursday, May 8th. Finally, Erste Group Bank upgraded AbbVie to a "strong-buy" rating in a research report on Monday, March 17th. Eight analysts have rated the stock with a hold rating, seventeen have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, AbbVie presently has an average rating of "Moderate Buy" and a consensus target price of $211.29.
View Our Latest Report on AbbVie
AbbVie Price Performance
ABBV stock traded up $0.97 on Wednesday, reaching $190.74. The company had a trading volume of 5,593,883 shares, compared to its average volume of 6,289,094. AbbVie Inc. has a 1 year low of $163.81 and a 1 year high of $218.66. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76. The company's fifty day moving average is $187.10 and its 200 day moving average is $188.78. The company has a market cap of $336.92 billion, a P/E ratio of 81.17, a PEG ratio of 1.28 and a beta of 0.48.
AbbVie (NYSE:ABBV - Get Free Report) last posted its earnings results on Friday, April 25th. The company reported $2.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.40 by $0.06. AbbVie had a return on equity of 412.03% and a net margin of 7.31%. The firm had revenue of $13.34 billion for the quarter, compared to analyst estimates of $12.91 billion. During the same quarter in the prior year, the company earned $2.31 EPS. AbbVie's revenue was up 8.4% on a year-over-year basis. On average, research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.
AbbVie Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Friday, August 15th. Shareholders of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a dividend yield of 3.44%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie's dividend payout ratio is presently 279.15%.
About AbbVie
(
Free Report)
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
Featured Stories
Before you consider AbbVie, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.
While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
